These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9689499)

  • 21. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
    Bérubé M; Poirier D
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
    Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
    Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
    Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
    J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
    Bydal P; Luu-The V; Labrie F; Poirier D
    Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes.
    Sam KM; Auger S; Luu-The V; Poirier D
    J Med Chem; 1995 Oct; 38(22):4518-28. PubMed ID: 7473580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
    Smuc T; Rizner TL
    Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells.
    Chetrite GS; Kloosterboer HJ; Philippe JC; Pasqualini JR
    Anticancer Res; 1999; 19(1A):261-7. PubMed ID: 10226552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of human placental 17 beta,20 alpha-hydroxysteroid dehydrogenase affinity alkylated by estrone 3-(bromoacetate): topographic studies with 16 alpha-(bromoacetoxy)estradiol 3-(methyl ether).
    Thomas JL; LaRochelle MC; Asibey-Berko E; Strickler RC
    Biochemistry; 1985 Sep; 24(20):5361-7. PubMed ID: 3865689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.